Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) Director Michael Joseph Driscoll sold 25,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Organogenesis Trading Down 6.2 %
Organogenesis stock opened at $5.64 on Friday. The firm has a 50-day moving average of $3.61 and a 200-day moving average of $3.33. Organogenesis Holdings Inc. has a one year low of $2.17 and a one year high of $6.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The company has a market cap of $715.31 million, a price-to-earnings ratio of -94.00 and a beta of 1.66.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upped their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research note on Wednesday.
Check Out Our Latest Analysis on ORGO
Institutional Investors Weigh In On Organogenesis
A number of institutional investors and hedge funds have recently modified their holdings of the company. Soleus Capital Management L.P. raised its holdings in shares of Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock valued at $39,952,000 after purchasing an additional 645,000 shares during the period. Assenagon Asset Management S.A. raised its holdings in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock valued at $9,443,000 after acquiring an additional 1,035,120 shares during the period. Dimensional Fund Advisors LP raised its holdings in Organogenesis by 18.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after acquiring an additional 442,772 shares during the period. State Street Corp raised its holdings in Organogenesis by 0.6% in the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock valued at $4,175,000 after acquiring an additional 9,090 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Organogenesis by 31.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock valued at $3,435,000 after acquiring an additional 255,600 shares during the period. 49.57% of the stock is owned by institutional investors.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
